Eli Lilly's Omvoh (mirikizumab) shows early and lasting relief in bowel urgency for patients with ulcerative colitis, reducing severity and frequency by over 50 percent in the Phase 3b LUCENT URGE study.
.png)
Lupin Digital Health, India’s leading cardiac digital-therapeutics company, has launched VITALYFE, an AI-powered cardiometabolic wellness platform designed to help India’s professionals improve their heart health...
Roche today announced that it has been awarded CE mark for its Elecsys Dengue Ag test, a high-throughput, completely automated immunoassay intended to support the diagnosis of acute dengue virus infection. This achievement represents a...
Merck & Co. and Eisai Co., Ltd. reported that their kidney cancer drug combo of Welireg and Lenvima met one main goal in a late stage trial for advanced renal cell carcinoma. The combo showed a significant improvement in progression free...
GSK has signed a global exclusive deal with Syndivia - a privately-held biotech dedicated to developing next-generation antibody-drug conjugates (ADCs) - for the advancement and commercialization of a preclinical ADC for patients with metastatic...
According to Novartis' announcement, APPLAUSE-IgAN randomized Phase III trial results have provided positive final results showing that Fabhalta (iptacopan) was demonstrated to significantly slow decline in kidney function in adults with IgA...
.png)
AstraZeneca's Imfinzi (durvalumab) has demonstrated a significant increase in survival for early-stage gastric (GC) and gastroesophageal junction cancers (GEJC), according to new data from the European Society for Medical Oncology (ESMO) 2025...
Biocon Biologics Ltd (BBL) has reached significant achievement with Health Canada's approval of Yesintek (ustekinumab injection) and Yesintek IV, which are biosimilars of Stelara and Stelara IV. The Notice of Compliance was issued on...
Johnson & Johnson announced impressive outcomes for a subcutaneous formulation of amivantamab (Rybrevant) which achieved a 45% overall response rate (ORR) in individuals with advanced head and neck squamous cell carcinoma (HNSCC)...
Novartis announced that Cosentyx met its primary endpoint and all secondary endpoints in the Phase III REPLENISH study, a significant milestone in the treatment of polymyalgia rheumatica. At Week 52, Cosentyx demonstrated statistically...
, CDSCO.jpg)